ClinicalTrials.gg
RecruitingNCT07255872Updated Sep 10, 2026

A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

A Phase 2/3 interventional study of BL-M11D1 and Cytarabine in Acute Myeloid Leukemia, sponsored by Sichuan Baili Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Sichuan Baili Pharmaceutical Co., Ltd. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
216
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Planned enrollment
26th of 239
216 · median 48
Started
2026
with 5 others
Phase 2/3
6 of 247
4 open now
Primary completion
2027-12
later than 19 of 44 live
Registered
239th of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 26th largest by planned enrollment of the 239 interventional ones that give a count, is one of 6 that started in 2026, is one of 6 in phase 2/3, reaches primary completion later than 19 of the 44 other live ones, and was the 239th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

33 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study is an open, multicenter, dose-escalation and expansion, non-randomized phase II/III clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M11D1 in combination with cytarabine + daunorubicin or venetoclax + azacitidine in patients with acute myeloid leukemia.

Read the detailed description

The study cohorts include: Cohort A: Untreated newly diagnosed acute myeloid leukemia patients treated with BL-M11D1 in combination with cytarabine + daunorubicin. Cohort B: Untreated newly diagnosed acute myeloid leukemia patients treated with BL-M11D1 in combination with venetoclax + azacitidine.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily sign the form and comply with the protocol requirements;
  2. No gender restrictions;
  3. Age: ≥18 years;
  4. Expected survival time ≥3 months;
  5. Newly diagnosed AML according to the World Health Organization (WHO) 2016 classification and confirmed by morphology;
  6. performance status score ≤2;
  7. Peripheral blood white blood cell count ≤25×10⁹/L before the first dose;
  8. Organ function levels must meet the requirements;
  9. For premenopausal women with , a pregnancy test must be performed within 7 days before starting treatment, and the serum/urine pregnancy test must be negative. Patients must not be breastfeeding; all enrolled patients (regardless of male or female) should adopt adequate barrier throughout the entire treatment cycle and for 6 months after the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia;
  2. Previous treatment for AML;
  3. Participation in other interventional or observational studies;
  4. History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;
  5. Prolonged , complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia;
  6. Active diseases and inflammatory diseases;
  7. Diagnosis of other within 5 years prior to the first dose;
  8. Poorly controlled hypertension;
  9. Grade ≥3 lung disease as defined by v5.0, history of interstitial lung disease requiring systemic therapy, etc.;
  10. Patients with central nervous system involvement;
  11. Previous organ transplantation;
  12. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any component of BL-M11D1;
  13. Positive antibody, active tuberculosis, active virus infection, or active virus infection;
  14. Evidence of other , poorly controlled infections requiring systemic treatment;
  15. Clinically symptomatic or recurrent pleural, peritoneal, pelvic, or pericardial effusion requiring drainage;
  16. Pregnant or lactating women;
  17. Within 4 weeks prior to the first dose of the study drug, subjects must not have received any or are not expected to receive live vaccines during the study participation;
  18. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    BL-M11D1 in Combination with Cytarabine + Daunorubicin or Venetoclax + Azacitidine

    Participants receive BL-M11D1 in Combination with Cytarabine + Daunorubicin or Venetoclax + Azacitidine for the first cycle (4 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

    Drug: BL-M11D1 · Drug: Cytarabine · Drug: Daunorubicin · Drug: Venetoclax · Drug: Azacitidine

Interventions

  • Administration by intravenous infusion for a cycle of 4 weeks.

  • Administration in 4-week cycles.

  • Administration in 4-week cycles.

  • Administration in 4-week cycles.

  • Administration in 4-week cycles.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.

    Time frame: Up to approximately 24 months

  2. Composite Response Rate(CRc)

    CRc is defined as the proportion of patients who achieve any one of several pre-defined types of treatment response.

    Time frame: Up to approximately 24 months

  3. Phase IIa: Recommended Phase II Dose (RP2D)

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M11D1.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Progression-free survival (PFS)

    Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.

    Time frame: Up to approximately 24 months

  2. Disease Control Rate (DCR)

    The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD\]).

    Time frame: Up to approximately 24 months

  3. Relapse-Free Survival (RFS)

    Relapse-Free Survival (RFS) is defined as the time from randomization (or from the start of treatment for non-randomized studies) until the first occurrence of disease recurrence or death from any cause.

    Time frame: Up to approximately 24 months

  4. Treatment-Emergent Adverse Event (TEAE)

    TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M11D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M11D1.

    Time frame: Up to approximately 24 months

  5. Cmax

    Maximum serum concentration (Cmax) of BL-M11D1 will be investigated.

    Time frame: Up to approximately 24 months

  6. Tmax

    Time to maximum serum concentration (Tmax) of BL-M11D1 will be investigated.

    Time frame: Up to approximately 24 months

  7. Ctrough

    Ctrough is defined as the lowest serum concentration of BL-M11D1 prior to the next dose will be administered.

    Time frame: Up to approximately 24 months

  8. ADA (anti-drug antibody)

    Frequency of anti-BL-M11D1 antibody (ADA) will be investigated.

    Time frame: Up to approximately 24 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality, China
    Recruiting
    • Jianxiang Wang · Contact
    • Jianxiang Wang · Principal investigator
    • Hui Wei · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 31 phase 2/3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 86. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Dec 1, 2025
StartActual
Apr 2, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07255872
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Dec 1, 2025
Start date
Apr 2, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Sa Xiao, PHD
Contact
xiaosa@baili-pharm.com
15013238943

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-CD33 Antibody-drug Conjugate BL-M11D1 · Cytarabine · Daunorubicin · Venetoclax · Azacitidine

Start the discussion